Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac (NASDAQ:CVAC) reported its Q4 and full-year 2024 financial results, marking a year of strategic transformation. The company completed enrollment for Part B of its Phase 1 glioblastoma study, with data readout expected in H2 2025. The FDA cleared their sqNSCLC Phase 1 study to begin in H2 2025.
Key financial highlights include a strong cash position of €481.7 million as of December 31, 2024, with runway extended into 2028. Full-year 2024 revenues reached €535.2 million, including a €400 million upfront payment from GSK licensing agreement. The company reported an operating profit of €177.7 million for 2024.
Notable developments include a positive ruling from the European Patent Office confirming CureVac's patent validity in proceedings against BioNTech SE, with a U.S. jury trial postponed to September 2025. The company also received a €10 million milestone payment for initiating Phase 1 of a seasonal influenza/COVID-19 combination vaccine study with GSK.
CureVac (Nasdaq: CVAC), a global biotech company focused on developing mRNA-based transformative medicines, has scheduled its Fourth Quarter and Full-Year 2024 Financial Results announcement for April 10, 2025.
The company will host a conference call and webcast at 3 p.m. CET / 9 a.m. EST on the same day. Investors and interested parties can access the event through U.S. Toll-Free (+1-877-407-0989), International (+1-201-389-0921), and German landline (0800-182-0040) or cell phone (0800-184-4713) numbers.
Presentation slides will be available before the webcast through CureVac's website newsroom section, with a replay available afterward.
CureVac (Nasdaq: CVAC) has received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 1 clinical trial of CVHNLC in squamous non-small cell lung cancer (sqNSCLC) patients. CVHNLC is an mRNA-based precision immunotherapy encoding eight tumor-associated antigens.
The trial will evaluate CVHNLC in combination with pembrolizumab, featuring two parts:
- Part A: dose-escalation study (100μg to 400μg) as first-line maintenance treatment
- Part B: optional dose expansion testing CVHNLC with first-line chemotherapy and pembrolizumab
Primary endpoints include dose-limiting toxicities and treatment-related adverse events, while secondary endpoints cover overall response rate, progression-free survival, and disease control rate. Patient treatment is expected to begin in the second half of 2025, with additional oncology candidates planned for clinical trials in 2026.
CureVac (NASDAQ:CVAC) has achieved a significant legal victory as the European Patent Office (EPO) largely dismissed BioNTech SE's opposition to CureVac's patent EP 3 708 668 B1, maintaining it in amended form. The patent covers CureVac's split poly-A tail technology, a foundational invention that enhances medical efficacy by improving protein expression in mRNA constructs.
This ruling marks a important milestone in the broader patent litigation between CureVac and BioNTech in Germany, which involves six intellectual property rights. An infringement hearing is scheduled for July 1, 2025, at the Regional Court Düsseldorf. If the court rules in CureVac's favor regarding infringement, it will trigger proceedings to assess damages.
CureVac (Nasdaq: CVAC) has been recognized as a Top 100 Global Innovator by LexisNexis® for the third consecutive year (2023-2025), highlighting its dynamic innovation and extensive intellectual property portfolio in mRNA technology. The recognition is based on the company's patent portfolio quality and advancement, evaluated through the Innovation Momentum methodology and Patent Asset Index.
As a pioneer in mRNA therapeutics, CureVac has developed proprietary foundational technologies over 25 years in mRNA design, delivery, and manufacturing. The company maintains one of the field's most comprehensive patent portfolios, with approximately 1,000 issued patents covering mRNA technology, manufacturing, and mRNA-based vaccines and therapies. These innovations have contributed significantly to COVID-19 vaccine development and other medical advances.
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on treating neuropathic corneal pain and inflammatory dry eye disease, announces its participation in the 4th Annual Virtual BTIG Ophthalmology Day on December 2nd, 2024. CEO Gary S. Jacob will engage in one-on-one meetings and lead a fireside chat from 2:40-3:15pm.
The event will feature over 20 medical technology and biotechnology companies, discussing latest developments in ophthalmic technologies and therapeutics. OKYO is developing treatments for NCP, which currently lacks FDA-approved therapies, and DED, representing a multi-billion-dollar market opportunity.
CureVac reported a transformative Q3 2024, marked by a €400 million upfront payment from a restructured GSK collaboration, increasing cash position to €551 million with runway extended into 2028. The company's Phase 1 glioblastoma study showed promising results with 77% of patients demonstrating antigen-specific T-cell responses. A new off-the-shelf program for squamous non-small cell lung cancer and a preclinical vaccine program for urinary tract infections were initiated. The company is implementing a 30% workforce reduction for cost savings from 2025. Q3 revenues reached €493.9 million, primarily driven by the GSK agreement. Operating profit was €368.4 million for Q3 2024.
CureVac (Nasdaq: CVAC) has announced it will release its third quarter and first nine months 2024 financial results on November 12, 2024. The company will host a conference call and webcast at 3 p.m. CET / 9 a.m. EST on the same day. The event will include financial results presentation and business updates. Investors can access the webcast through CureVac's website, where presentation slides will be available before the event, and a replay will be provided afterward.
CureVac has appointed Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024. Malkomes brings over 30 years of senior corporate and investment banking experience in biotech and pharmaceutical industries. He most recently served as CFO at Cardior Pharmaceuticals, where he led significant financing rounds culminating in its acquisition by Novo Nordisk in 2024. Previously, he was CFO and Chief Business Officer at Medigene AG and held senior roles at Barclays, Société Générale, and 3i Group plc. He currently serves on the Board of Directors of Cellectis SA, chairing its audit committee.
CureVac (Nasdaq: CVAC) announced upcoming presentations at the 12th International mRNA Health Conference in Boston, November 12-14, 2024. The company will share two oral presentations and four posters, featuring expanded data from their Phase 1 CVGBM cancer vaccine study in glioblastoma patients. Initial results showed 77% of evaluable patients developed cancer antigen-specific T-cell responses, with 84% of immune responses being vaccine-generated.
The presentations will include detailed safety and immunogenicity data from the dose escalation study, along with CureVac's approach to optimizing LNP delivery. Additional posters will showcase the company's mRNA platform optimization strategies and new development targets in oncology and infectious disease areas.
